Article FDA Thank You In unanimous decision, Supreme Court solves FDA’s ‘standing’ issue
Agency IQ
JUNE 17, 2024
They were not subject to any direct regulation by the FDA related to mifepristone. And in many cases, they had what the FDA had characterized as a “diametrically opposed” or “antagonistic” relationship with patients who have taken mifepristone at the direction of another medical provider. They were not purchasing mifepristone.
Let's personalize your content